J Cancer
2016; 7(10):1317-1327.
doi:10.7150/jca.15157 This issueCite
Research Paper
Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma
Tiejun Li1,2,3, Yuwen Xue1, Guilan Wang1, Tingting Gu1, Yunlong Li1, York Yuanyuan Zhu2,3✉, Li Chen1✉
1. Department of Pathological Anatomy, Nantong University, Nantong, China; 2. Small RNA Technology and Application Institute, Nantong University, Nantong, China; 3. Biomics Biotechnologies Co., Ltd., Nantong, China.
✉ Corresponding authors: Li Chen, Professor. Department of Pathological Anatomy, Nantong University, 19 Qixiu Road, Nantong 226001, Jiangsu, China. Email: bl1edu.cn. York Yuanyuan Zhu, Ph.D. Small RNA Technology and Application Institute, Nantong University, 76 Changxing Road, E&T Development Area, Nantong 226016, China. Email: yzhucom. Tel: +86-513-85051729; Fax: +86-513-85051729.More
Citation:
Li T, Xue Y, Wang G, Gu T, Li Y, Zhu YY, Chen L. Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma. J Cancer 2016; 7(10):1317-1327. doi:10.7150/jca.15157. https://www.jcancer.org/v07p1317.htm
Multiple targets RNAi strategy is a preferred way to treat multigenic diseases, especially cancers. In the study, multi-target siRNAs were designed to inhibit NET-1, EMS1 and VEGF genes in hepatocellular carcinoma (HCC) cells. And multi-target siRNAs showed better silencing effects on NET-1, EMS1 and VEGF, compared with single target siRNA. Moreover, multi-target siRNA showed greater suppression effects on proliferation, migration, invasion, angiogenesis and induced apoptosis in HCC cells. The results suggested that multi-target siRNA might be a preferred strategy for cancer therapy and NET-1, EMS1 and VEGF could be effective targets for HCC treatments.
Li, T., Xue, Y., Wang, G., Gu, T., Li, Y., Zhu, Y.Y., Chen, L. (2016). Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma. Journal of Cancer, 7(10), 1317-1327. https://doi.org/10.7150/jca.15157.
ACS
Li, T.; Xue, Y.; Wang, G.; Gu, T.; Li, Y.; Zhu, Y.Y.; Chen, L. Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma. J. Cancer 2016, 7 (10), 1317-1327. DOI: 10.7150/jca.15157.
NLM
Li T, Xue Y, Wang G, Gu T, Li Y, Zhu YY, Chen L. Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma. J Cancer 2016; 7(10):1317-1327. doi:10.7150/jca.15157. https://www.jcancer.org/v07p1317.htm
CSE
Li T, Xue Y, Wang G, Gu T, Li Y, Zhu YY, Chen L. 2016. Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma. J Cancer. 7(10):1317-1327.